论文部分内容阅读
目 的:生物转化酶细胞色素P4502D6(CYP2D6)和谷胱苷肽转移酶－M1(GST－M1)、谷胱苷肽转移酶－T1(GST－T1)共同代谢内源性和外源性毒素,一部分人群由于相应基因变异导致这些酶缺乏表达,我们检测白种人群中晚期肾病(ESRD)病人这些酶的基因多态性是否比健康者有较高的频率。方法:从列克星顿及周围地区征募330名晚期肾病病人和303名健康者,均为白种人,给予他们进行CYP2D6和GST－M1和T1基因分型。结果:在ESRD病人中CYP2D6和GST－M1和GST－T1以及CYP2D6和GST－M1或GST－T1都缺乏分别为2.1%和4．2%;而在健康者中均为0.3%(P＜0.01)。结论:CYP2D6和GST-M1和域GST－T1酶缺乏在ESRD病人中有较高的频率,提示这些酶缺乏可以预计慢性肾病进展的可能性。
Objective: The biotransformation enzymes CYP2D6 and GST-M1, GST-T1 co-metabolize endogenous and exogenous toxins, In some populations, due to the lack of expression of these enzymes due to the corresponding genetic variations, we examined whether genetic polymorphisms in these enzymes in patients with advanced kidney disease (ESRD) in the Caucasian population were higher than those in healthy individuals. Methods: 330 late kidney disease patients and 303 healthy subjects were recruited from and around Lexington, both Caucasian, and were given CYP2D6 and GST-M1 and T1 genotyping. Results: The lack of CYP2D6 and GST-M1 and GST-T1, and CYP2D6 and GST-M1 or GST-T1 in ESRD patients were 2.1% and 4.2%, respectively, and in healthy controls 0.3% (P <0.01) ). CONCLUSIONS: CYP2D6 and GST-M1 and domain GST-T1 enzyme deficiency have a high frequency in ESRD patients, suggesting that the lack of these enzymes predicts the likelihood of progression of chronic kidney disease.